Resources

Help yourself to our online catalogue of useful information, including annual reports, scientific and clinical trial publications, infographics and more.

Filter by language:
Filter by category:
Search resources:
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Newsletter
22 Dec 2020

Newsletter Volume 4

September 2021

Learn about MDGH's expanded footprint, its progress in clinical development, a social impact investment opportunity, and the nominations for the Prix Galien Award for 2021

Protocol
22 Dec 2020

Moxidectin in Onchocerciasis: Ongoing Clinical Trial Protocols

MDGH-MOX-3001: Safety and efficacy of annual or biannual doses of moxidectin or ivermectin for onchocerciasis​ (Target: approx. 1,000 participants)​.

Protocol
22 Dec 2020

Moxidectin in Onchocerciasis: Ongoing Clinical Trial Protocols

MDGH-MOX-3002: Safety of a single dose of moxidectin compared with ivermectin in individuals living in onchocerciasis-endemic areas (Target: approx. 12,500 participants).

Newsletter
22 Dec 2020

Newsletter Volume 3

June 2021

A look at the 2020 MDGH Annual Report, clinical development updates, and the development of a new formulation of moxidectin for children.

Newsletter
22 Dec 2020

Newsletter Volume 2

March 2021

Learn more about MDGH's plans for its new investigational treatment for tuberculosis and leprosy types 2 reactions.

Annual Report
22 Dec 2020

2020 Annual Report

MDGH celebrated its 15th anniversary in 2020. Our 2020 Annual Report documents our progress as well as our current thinking on our contribution to neglected disease R&D and access to medicines.

Peer-reviewed publication
22 Dec 2020

Phase 3 Clinical Trials: Moxidectin for Onchocerciasis

Opoku NO, Bakajika DK, Kanza EM, et al. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial. Lancet. 2018;392(10154):1207-1216

Peer-reviewed publication
22 Dec 2020

Phase 2 Clinical Trials: Moxidectin for Onchocerciasis

Awadzi K, Opoku NO, Attah SK, Lazdins-Helds J, Kuesel AC. A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection. PLoS Negl Trop Dis. 2014;8(6):e2953.

Peer-reviewed publication
22 Dec 2020

Modelling

Turner HC, Walker M, Attah SK, et al. The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data. Parasit Vectors. 2015;8:167.

Peer-reviewed publication
22 Dec 2020

Onchocerciasis Review

Prichard RK, Geary TG. Perspectives on the utility of moxidectin for the control of parasitic nematodes in the face of developing anthelmintic resistance. Int J Parasitol Drugs Drug Resist. 2019;10:69-83.

Peer-reviewed publication
22 Dec 2020

Onchocerciasis Review

Boussinesq M, Fobi G, Kuesel AC. Alternative treatment strategies to accelerate the elimination of onchocerciasis. Int Health. 2018;10(suppl_1):i40-i48.

Peer-reviewed publication
22 Dec 2020

Phase 1 Clinical Trials: Moxidectin

Kinrade SA, Mason JW, Sanabria CR, et al. Evaluation of the cardiac safety of long-acting endectocide moxidectin in a randomized concentration-QT study. Clin Transl Sci. 2018;11(6):582-589.

Peer-reviewed publication
22 Dec 2020

Phase 1 Clinical Trials: Moxidectin

Korth-Bradley JM, Parks V, Chalon S, et al. Excretion of moxidectin into breast milk and pharmacokinetics in healthy lactating women. Antimicrob Agents Chemother.2011;55(11):5200-5204.

Peer-reviewed publication
22 Dec 2020

Phase 1 Clinical Trials: Moxidectin

Korth-Bradley JM, Parks V, Patat A, Matschke K, Mayer P, Fleckenstein L. Relative Bioavailability of Liquid and Tablet Formulations of the Antiparasitic Moxidectin. Clin Pharmacol Drug Dev. 2012;1(1):32-37.

Protocol
22 Dec 2020

Onchocerciasis Review

Milton P, Hamley JID, Walker M, Basanez MG. Moxidectin: an oral treatment for human onchocerciasis. Expert Rev Anti Infect Ther. 2020:1-15. 10.1080/14787210.2020.1792772

Protocol
22 Dec 2020

Moxidectin in Onchocerciasis: Ongoing Clinical Trial Protocols

MDGH-MOX-1006: A pharmacokinetic and safety study of moxidectin to identify an optimal dose for treatment of children 4 to 11 years (Target: at least 27 participants).

Load more